Medical network - April 18 people club department general office recently issued announcement said, according to the new directory to negotiate drug, and communication with the enterprises producing intention to negotiate, ultimately determine the scope included in the negotiations of the department of 44 varieties of drugs. Surprised the industry, eventually going into the scope of medicine of the enterprise, the breakthrough of local drug firms accounted for half of our country. 

 

Expert thinks, this means that the negotiations have long been foreign drug companies dominate the drug areas have begun to show the tendency of localization, but also has a point of view, said most foreign drug companies to participate in medical maintain wait-and-see attitude, so negotiations enthusiasm is not high. 

 

▍ domestic medicine catalogue of drugs to be shortlisted for the negotiation of the "groups" 

 

Adjustment for the first time in eight years before the implementation of national health care medicine directory finally entered the final sprint phase. , according to a new version of the medical insurance directory containing drug number for 2535, from 2009, 339 new version catalogue, rising by about 15%. Among them, the western medicine, 1297, proprietary Chinese medicine 1297 (including ethnic medicine, 88), Chinese medicine yinpian do not adjust, still continue to use the provisions of the 2009 drugs directory. Notable is, this year the new directory also confirmed that 45 to negotiate drug. Drugs, these drugs are usually innovation high clinical value and expensive, for cancer and other incurable diseases have better therapeutic effect. 

 

According to statistics, in people club department released the latest talks will eventually 44 drug species, including the domestic medicine 18 and 26 foreign drug companies products, corresponding to the shortlisted for the medicine enterprises in our country local pharmaceutical companies and the number of foreign companies is 17 and 15 respectively. By calculation, going into the drug firms, medicines, our native enterprises and the proportion of drug number account for 53% and 53% respectively. Previously, the media and industry analysts have predicted that admiration domestic may be shortlisted for the variety of drugs is only single digits. 

 

Lower drug prices high in China, in fact, an important part of reform and exploration, price negotiation system's original intention is the way through negotiated the price higher patent medicine and exclusive production of drugs price fell to a reasonable range. And it has been a common international practices. 

 

In may last year, China announced the first batch of national health insurance directory negotiations as a result, finally has the three drugs, among them, the first-line treatment for chronic hepatitis b drug tenofovir ester, ek for non-small cell lung cancer targeted therapy drugs, the treatment and three kinds of drug reduction reached 67%, 54% and 54%, respectively, among them, tenofovir ester is more down to the global price of the drug. In contrast, negotiated before, tenofovir ester, ek for the treatment and the cost price of as high as 1500 yuan, 12000 yuan and 15000 yuan respectively. 

 

▍ foreign drug companies "wait and see" the mood is still strong 

 

Some experts believe that the people club department released the final version of negotiation directory released a clear signal, which originally was thought to be the foreign drug companies negotiations "home" in the field of medicine, the comparison of domestic and foreign enterprises the gap is narrowing, a large number of domestic new drugs and generic substitution degree of the original varieties are rapidly. 

 

There is no denying the fact that large scale of total drug consumption market in China, and the subsequent growth potential is still huge. , as the world's second largest pharmaceutical market in the context of the global economic slowdown, China's drug consumption market was once foreign drug companies as a safe haven, and this has also led to China's high-end medical market exists long-term monopolized by foreign companies. 

 

However, for the drug negotiations said high-end market pattern changes, the industry doesn't see eye to eye. Experts said the high price of foreign drug companies producing cancer drugs, though, but certain drugs on the treatment effect is irreplaceable, and it also caused the foreign drug firms have enough "style" need not sharpening head to squeeze into medical insurance directory. "In fact, some relative last year actively involved in the negotiations, to join the medical insurance directory of foreign drug companies, partly due to negative news with lead to lower sales, only hope to pass into the health care to the amount in price revive sales. The drug companies for drug does so tripled sales." The experts said. 

 

Zhao Heng senior medical experts also, according to the analysis of the present stage, more and more foreign drug companies will be low margin products "abandoned", instead will mainly focus on high profits and high price of high-end medicine, because these drugs itself is rigid demand products, even if you don't enter our country medical insurance directory can guarantee a certain number of sales. "Can dramatically reduce the selling price into health although impulse, but it is not clear whether the benefits of high cost performance, lead to most foreign drug firms still wait." Zhao Heng said. 

 

▍ negotiations drugs into health care long long way to go 

 

"At present, the reform of price negotiation in the process is relatively in line with expectations, the future in the coverage gradually widened at the same time, more medicines, especially high-end medicine is increasingly strict price control is still the mainstream trend." Zhao Heng said. 

 

In fact, the expert inside course of study is not the minority, similar to that of the Zhao Heng view, they say, in the backdrop of the national overall price reduction, take nobleman medicine operation will be inevitable. National health development planning commission, deputy director of the original sun zhigang has stressed that "Chinese patent medicine to buy now and exclusive rights to produce drug prices artificially high generally, we want to be able to negotiate, with huge market demand in exchange for a lower and reasonable price". 

 

To squeeze out the price of patent medicine moisture, in October 2015, approved by the state council, the state development planning commission and other 16 departments jointly established drug price negotiation joint inter-ministerial meeting system and establish the coordination mechanism, organize the first pilot work, the state department of pharmaceutical price negotiations negotiations aimed at patent medicines and exclusive domestic production of drugs. It is reported, the pilot work organization experts comprehensive combing the selection of domestic patent medicines, the sole drug production condition, finally chose the high price, heavy burden of disease, patients benefit from obvious remedial second liver, lung cancer and multiple myeloma pilot drug patent medicine as a negotiation. Subsequently, experts established the negotiating team, take "a drug policy" refining the negotiation process. 

 

Shortly after the talks ended, relevant departments will release around the policy requirements in a timely manner the negotiation results open the net on the provincial drug centralized purchasing platform, medical institutions directly online purchasing negotiation price. And, in 2016-2017, the purchasing cycle, no longer separate organizations around the bargaining negotiations, and to encourage prior purchasing drugs and the use of negotiation. 

 

, however, the research of Chinese medicine institute, director of the center for Song Ruilin view, "reduced price" and "health care" is not a causal relationship, "the national drug negotiation is not health, provincial health care management, financing platform, financing ability is different, after negotiations wanted to quickly enter the provincial health care, drugs do have difficulty". And after the club head of media in WeChat public, made it clear that drug comprehensive negotiations into health care, don't rush. This paper points out that a drug is included in the health care, looks very simple, behind is a very rigorous assessment process.